Clinical Trial Update: Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating PMI-150 intranasal ketamine for breakthrough cancer pain was terminated; the update references safety and efficacy data collected pri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• PMI-150 (intranasal ketamine) (ketamine)

Snippet

Sponsor: Hospira, now a wholly owned subsidiary of Pfizer | Conditions: Pain, Cancer | Phase 3 | Status: TERMINATED